Stifel Nicolaus reiterated their buy rating on shares of Galapagos NV (NASDAQ:GLPG) in a research note published on Sunday morning. Stifel Nicolaus currently has a $120.00 target price on the biotechnology company’s stock.

Other analysts also recently issued reports about the stock. Morgan Stanley restated an overweight rating and issued a $92.00 target price on shares of Galapagos NV in a report on Thursday, August 10th. Cowen and Company restated a buy rating on shares of Galapagos NV in a report on Thursday, August 10th. Janney Montgomery Scott upgraded shares of Galapagos NV from a sell rating to a neutral rating in a report on Friday, July 7th. They noted that the move was a valuation call. BidaskClub upgraded shares of Galapagos NV from a sell rating to a hold rating in a report on Thursday, August 17th. Finally, Nomura boosted their target price on shares of Galapagos NV from $108.00 to $124.00 and gave the stock a buy rating in a report on Friday, August 11th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $108.14.

Shares of Galapagos NV (NASDAQ:GLPG) traded down 0.12% on Friday, hitting $97.05. The stock had a trading volume of 96,718 shares. Galapagos NV has a 12 month low of $57.16 and a 12 month high of $104.12.

COPYRIGHT VIOLATION NOTICE: “Galapagos NV (GLPG) Given “Buy” Rating at Stifel Nicolaus” was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/10/30/galapagos-nv-glpg-given-buy-rating-at-stifel-nicolaus.html.

A number of large investors have recently modified their holdings of GLPG. Karp Capital Management Corp bought a new position in Galapagos NV during the 1st quarter valued at about $206,000. UBS Group AG grew its holdings in Galapagos NV by 237.0% during the 1st quarter. UBS Group AG now owns 3,522 shares of the biotechnology company’s stock valued at $303,000 after purchasing an additional 2,477 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Galapagos NV by 51.4% during the 1st quarter. Renaissance Technologies LLC now owns 311,200 shares of the biotechnology company’s stock valued at $26,822,000 after purchasing an additional 105,700 shares during the last quarter. Bank of America Corp DE grew its holdings in Galapagos NV by 18.8% during the 1st quarter. Bank of America Corp DE now owns 4,379 shares of the biotechnology company’s stock valued at $377,000 after purchasing an additional 694 shares during the last quarter. Finally, Driehaus Capital Management LLC bought a new position in Galapagos NV during the 1st quarter valued at about $942,000. Institutional investors own 23.61% of the company’s stock.

Galapagos NV Company Profile

Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

Analyst Recommendations for Galapagos NV (NASDAQ:GLPG)

Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.